$heff's $tation of $tocks & $olid DD

[ash111]

PRSN .50,updated DD: what really Caught my eye,there is no other Biotech company trading under $4m Cap that FDA granted the company to market it's one-of-a-kind product and they marketing it right now.not to mention the huge increase on sales growing rate per last 10Q(sales increased 117%).

The cheapest biotech NASDAQ company(market cap under $4m),but still solid, Especially after recent developments:

per 10Q: Assets/debt ratio about 2-solid. this is before recent offering."In connection with the closing of the Company’s registered offering of common stock and warrants on August 4, 2015, the Company received net proceeds of approximately $4.3 million".The Company believes that with the addition of these net proceeds it is now in compliance with the Stockholders' Equity Rule as of the date of this Current Report on Form 8-K. way over the minimum required($2.5m) by Listing Rule 5550(b)(1).

Based on Risks/Rewards, i find this very interesting due to the very low and rare cap,The MicroThermX® sales growing rate(117%!,check below the numbers) and the fact that "The U.S. Food and Drug Administration (FDA) granted the company a 510(k) clearance to market the MicroThermX for ablation of soft tissue".

The company owns eight non-expired patents in the United States related to certain components or technology of its ablation and hyperthermia systems. The company has one patent license from Duke University. 11 new U.S. patent applications have been published in the United States, and 1 foreign patent is issued and others are pending. A total of 29 U.S. patents have been issued to the company. Government Regulation The company’s products sold in the United States are subject to the Federal Food, Drug, and Cosmetic Act (FDCA), as implemented and enforced by the FDA. Certain of the company’s products sold in the United States require FDA clearance to market under Section 510(k) of the FDCA. History The company was incorporated under the laws of the state of Utah in 1978 and was reincorporated in the state of Delaware in 1986. It was formerly known as BSD Medical Corporation and changed its name to Perseon Corporation in 2015.

TODAY:will present at the Rodman & Renshaw 17th Annual Global Investment Conference being held at The St. Regis Hotel, New York City. Clint Carnell, Chief Executive Officer, will provide an overview of Perseon and its strategy at 11:40 a.m. Eastern time on Thursday, September 10, 2015.
Perseon's presentation will be webcast live and archived for 90 days on the Events and Presentations page at http://perseonmedical.com.

Insiders bought 155000 shares at 0.88 last month:
https://www.holdingschannel.com/insider-buying/prsn-insider-buying/

10Q:
Perseon Announces Fiscal Year 2015 Second Quarter Results; MicroThermX(R) Revenue Grows 117% Year-over-Year

Q2 2015 Revenues Driven Solely by the Company's MicroThermX® Business
MicroThermX Revenues More than Doubled Year-over-Year
Reiterates Revenue Guidance of $3.5 Million to $5.0 Million for FY 2015

SALT LAKE CITY, July 16, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (NASDAQ:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced financial results for the second quarter ended June 30, 20151.

Second Quarter Highlights and Commentary

Executing three-year strategic plan focused on the disruptive high growth energy ablation market
MicroThermX® sales increased 117% year-over-year
Gross margins improved to 66% from 41% a year ago, reflecting sole focus on higher margin MicroThermX business
Perseon expects total MicroThermX revenues to range between $3.5 million to $5.0 million in fiscal year 2015, up 67% to 138% over 2014

Market potential: MicroThermX :

The one-of-a-kind microwave ablation system providing the perfect balance of precise control, flexibility and power.

Physicians who need to ablate soft tissue tumors, both malignant and benign, prefer the MicroThermX microwave ablation system because its 915 MHz frequency results in a deeper penetration into the tissue. Physicians get more power and, at the same time, more control when removing tumors in organs such as lung, liver, and kidney.

When larger ablation zones are required physicians rely on the Synchronous Wave Alignment technology of MicroThermX. Using multiple Perseon antenna tips increases the probability of reaching the center of large tumors and creating larger margins to ensure that all of the surrounding cells are eliminated.

Due to the flexibility of the system physicians use MicroThermX in open surgical procedures and percutaneous ablations. It consists of a single generator and amplifier that deliver microwave energy to single or multiple antenna(s).

The system is not intended for use in cardiac procedures. It is contraindicated in patients with pacemakers or other active electronic device implants and in pregnant women.

"With Perseon, you get a much bigger and better burn in a shorter amount of time."
— Dr. Sohail Contractor, Section Chief, Interventional Radiology Rutgers New Jersey Medical School

looks like a GEM. 52wk Range
0.34- 7.60